Lucinda Quan
Founder at ALIGOS THERAPEUTICS, INC.
Net worth: 314 770 $ as of 2024-04-29
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Lawrence Blatt | M | 62 |
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | 19 years |
Inge Thulin | M | 69 | 6 years | |
Carole Nüchterlein | F | 62 | 6 years | |
K. Hirth | M | 72 | 6 years | |
Jim Scopa | M | 65 | 3 years | |
Bridget Martell | M | 58 | 3 years | |
Jennifer Zachary | F | 46 | 6 years | |
Jordyn Tarazi | F | - | - | |
Dean Li | M | 62 | 7 years | |
Lesley Calhoun | F | 58 | 4 years | |
Eric Rubin | M | 65 | 6 years | |
Peter Dannenbaum | M | - | 7 years | |
Carla Fiankan | F | - | 13 years | |
Julian Symons | M | 63 | 6 years | |
Sushmita M. Chanda | M | 58 | 6 years | |
Kristina Engeseth | F | - | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Leonid Beigelman | M | 66 |
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | 15 years |
Jack Nielsen | M | 60 |
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | 13 years |
John C. Hodgman | M | 69 | - | |
Jonathan Leff | M | 55 | 12 years | |
John Noseworthy | M | 71 | - | |
Paul D. Arata | M | 69 | - | |
Thomas Woiwode | M | 52 | 5 years | |
Lars Ekman | M | 74 | 7 years | |
Peter Moldt | M | 65 | - | |
Frank Verwiel | M | 61 | 2 years | |
Kathleen Glaub | F | 70 | - | |
Angus Russell | M | 68 | 3 years | |
David Kabakoff | M | 76 | 9 years | |
Jean-Jacques Bienaimé | M | 70 | 2 years | |
Sheila Ranganath | F | - | 5 years | |
Louis C. Drapeau | M | 79 | 7 years | |
Andrew Powell | M | 66 | 2 years | |
Charles Kidder | M | 79 | 12 years | |
Natarajan Sethuraman | M | 62 | 10 years | |
Maria Rivas | M | 60 | 2 years | |
Roger Dansey | M | 67 | 3 years | |
Ken Johnson | M | 61 | 1 years | |
Arthur Santora | M | 73 | 28 years | |
Karen Akinsanya | M | 56 | 4 years | |
Rongqiang Liu | M | 58 | 4 years | |
Daniel Pascheles | M | - | 11 years | |
Joseph Eid | M | 56 | - | |
Kimberly Park | F | 60 | 4 years | |
Fariborz Kamal | M | 61 | 2 years | |
Francesco Maria Lavino | M | 51 | 2 years | |
Nancy Miller-Rich | F | 65 | 4 years | |
Robert Plenge | M | 53 | 4 years | |
Yuan Xu | M | 56 | 2 years | |
Arnaub Chatterjee | M | - | 5 years | |
Reshma Rangwala | M | 46 | 5 years | |
Amy Klug | F | - | - | |
Quentin Roach | M | 57 | 4 years | |
John Fry | M | - | 5 years | |
Matthew McClure | M | 53 | 5 years | |
Le-Van Nguyen | F | - | 2 years | |
Soren Christiansen | M | 68 | 19 years | |
Srikanth Venkatraman | M | - | 4 years | |
Christopher Galloway | M | 53 | 2 years | |
John Renger | M | 55 | 15 years | |
Marvin Johnson | M | 61 | 2 years | |
Lisa LeCointe-Cephas | F | 42 | 6 years | |
Joseph Arena | M | 69 | 1 years | |
Elizabeth Ann Fagan | M | 74 | 4 years | |
Jay Galeota | M | 57 | 28 years | |
Clark Golestani | M | 57 | 24 years | |
Michel Vounatsos | M | 62 | 20 years | |
Roy Baynes | M | 69 | - | |
Roger L. Hawley | M | 71 | 3 years | |
Steven Bryant Porter | M | 66 | 11 years | |
Thomas Kassberg | M | 63 | 3 years | |
Norman L. Halleen | M | 70 | 2 years | |
Cynthia Y. Robinson | M | 65 | 3 years | |
Willie Deese | M | 68 | 12 years | |
Jonathan Leff | M | 66 | 3 years | |
Alan Howard Cohen | M | 63 | - | |
Sean Nolan | M | 56 | 2 years | |
William Halter | M | 63 | 4 years | |
Jennifer D. Haldeman | F | 59 | 1 years | |
Karen S. Wright | F | 69 | 2 years | |
Heath Lukatch | M | 56 |
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | 5 years |
Michael Rosenblatt | M | 76 | 32 years | |
Michael Holston | M | 61 | 6 years | |
Guy Patrick M. Eiferman | M | - | 4 years | |
Bruce W. Tomlinson | M | 64 | 5 years | |
Mathai Mammen | M | 57 | 1 years | |
Mary Shoemaker | F | 63 | 1 years | |
Barrett S. McGrath | M | - | - | |
Erik Harris | M | 54 | 1 years | |
Simon D. Kelner | M | 51 | 13 years | |
Marianne A. Porter | M | 69 | 10 years | |
Steven Mizell | M | 64 | 8 years | |
Rosanne Roth | F | - | 2 years | |
Malcolm McKay | M | - | 4 years | |
Phillip Samayoa | M | 37 | - | |
Andrew Davis | M | 38 | 1 years | |
Renu Vaish | F | - | 1 years | |
Thomas Cannell | M | 62 | 1 years | |
Jonathan Robbins | M | - | 6 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 99 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Lucinda Quan
- Personal Network